Scarica l'app Stockscreener
22.28
2.72%
0.59
Dopo l'orario di chiusura:
22.40
0.12
+0.54%
Precedente Chiudi:
$21.69
Aprire:
$21.79
Volume 24 ore:
396.51K
Relative Volume:
0.81
Capitalizzazione di mercato:
$1.20B
Reddito:
$2.22M
Utile/perdita netta:
$-40.51M
Rapporto P/E:
-17.34
EPS:
-1.2847
Flusso di cassa netto:
$-46.53M
1 W Prestazione:
+12.58%
1M Prestazione:
+28.41%
6M Prestazione:
+164.61%
1 anno Prestazione:
-5.71%
Intervallo 1D:
$21.39
$22.39
Intervallo di 1 settimana:
$19.46
$22.39
Portata 52W:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Nome
Upstream Bio Inc
Settore
Industria
Telefono
781-208-2466
Indirizzo
890 WINTER STREET, SUITE 200, WALTHAM
Confronta UPB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
22.28 | 1.08B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Iniziato | William Blair | Outperform |
Upstream Bio Inc Borsa (UPB) Ultime notizie
Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting - Insider Monkey
What earnings revisions data tells us about Upstream Bio Inc.Trade Exit Report & Verified Short-Term Trading Plans - newser.com
How resilient is Upstream Bio Inc. stock in market downturnsPortfolio Value Report & Safe Entry Trade Signal Reports - newser.com
Truist Securities Initiates Coverage on Upstream Bio (UPB) with a Buy Rating | UPB Stock News - GuruFocus
Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential - Investing.com
Upstream Bio initiated with a Buy at Truist - TipRanks
Is Upstream Bio Inc. stock trading at a premium valuationWeekly Trading Summary & High Accuracy Trade Alerts - newser.com
What to do if you’re stuck in Upstream Bio Inc.July 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
Will Upstream Bio Inc. stock outperform growth indexesFed Meeting & Technical Confirmation Alerts - newser.com
Can Upstream Bio Inc. stock sustain revenue growthMarket Activity Summary & Risk Controlled Swing Trade Alerts - newser.com
Why Upstream Bio (UPB) Is Up 6.5% After Positive Phase 2 Results for Verekitug in Respiratory Diseases - Sahm
Upstream Bio's (UPB) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Will Rising Interest Rates Hurt Vintage Coffee and Beverages Limiteds Profit MarginsMonthly Performance Summary & Free Stop-Loss Planning for Your Portfolio - earlytimes.in
Measuring Upstream Bio Inc.’s beta against major indicesJuly 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - newser.com
What does recent volatility data suggest for Upstream Bio Inc.Weekly Profit Analysis & Stepwise Entry and Exit Trade Signals - newser.com
What drives Upstream Bio Inc stock priceVolume Weighted Average Price & Plan Your Future With Strategic Investing - earlytimes.in
Visualizing Upstream Bio Inc. stock with heatmapsJuly 2025 Rallies & Technical Analysis for Trade Confirmation - newser.com
Can volume confirm reversal in Upstream Bio Inc.Trade Entry Report & AI Forecasted Entry/Exit Points - newser.com
Applying Elliott Wave Theory to Upstream Bio Inc.July 2025 Setups & Daily Stock Trend Watchlist - newser.com
Upstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past Week - Yahoo
Assessing Upstream Bio (UPB) Valuation After New Verekitug Phase 2 Data and Investor Interest Surge - Sahm
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Why Upstream Bio (UPB) Is Up 14.0% After Positive Phase 2 Verekitug Data and Novel Dosing Approach - Sahm
News impact scoring models applied to Upstream Bio Inc.2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Is Upstream Bio Inc. forming a reversal patternJuly 2025 Update & Community Supported Trade Ideas - newser.com
Is Upstream Bio Inc. stock attractive for passive investorsMarket Growth Summary & AI Driven Stock Price Forecasts - newser.com
Earnings visualization tools for Upstream Bio Inc.July 2025 Earnings & Trade Opportunity Analysis - newser.com
Why retail investors pile into Upstream Bio Inc. stock2025 Market Outlook & Intraday High Probability Setup Alerts - newser.com
Upstream Bio Inc Stock Analysis and ForecastPrice Channel Trading & Free Popular Stock Picks Selection - earlytimes.in
Is Upstream Bio Inc. building a consolidation baseTrade Analysis Summary & Scalable Portfolio Growth Ideas - newser.com
Upstream Bio (NASDAQ:UPB) Trading 4.2% HigherStill a Buy? - MarketBeat
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - The Manila Times
Upstream Bio Presents Data Showing Structural and - GlobeNewswire
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
Upstream Bio Inc Azioni (UPB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):